Equities

Zomedica Corp

Zomedica Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.12
  • Today's Change-0.002 / -1.40%
  • Shares traded9.40m
  • 1 Year change-34.85%
  • Beta1.0327
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Zomedica Corp share price to rise to 0.44 in the next year from the last price of 0.12.
High266.7%0.44
Med266.7%0.44
Low266.7%0.44

Earnings history & estimates in USD

Earnings forecasts are not available for Zomedica Corp. On Nov 07, 2024, Zomedica Corp reported 3rd quarter 2024 losses of -- per share.
Average growth rate-445.00%
Zomedica Corp reported annual 2023 losses of -0.02 per share on Apr 01, 2024.
Average growth rate+36.84%
More ▼

Revenue history & estimates in USD

Zomedica Pharmaceuticals Corp. had 3rd quarter 2024 revenues of 7.00m. This was 27.64% above the prior year's 3rd quarter results.
Average growth rate+3.24%
Zomedica Pharmaceuticals Corp. had revenues for the full year 2023 of 25.19m. This was 33.05% above the prior year's results.
Average growth rate+33.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.